Theresa MS - Rain Therapeutics Director Operations
| RAINDelisted Stock | USD 1.41 0.01 0.70% |
Insider
Theresa MS is Director Operations of Rain Therapeutics
| Phone | 510 953 5559 |
| Web | https://www.rainoncology.com |
Rain Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5219) % which means that it has lost $0.5219 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9704) %, meaning that it created substantial loss on money invested by shareholders. Rain Therapeutics' management efficiency ratios could be used to measure how well Rain Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Rain Therapeutics currently holds 277 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Rain Therapeutics has a current ratio of 7.06, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Rain Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Avani Kanubaddi | Enveric Biosciences | 51 | |
| RPh PharmD | Elevation Oncology | 40 | |
| MBA IV | Enveric Biosciences | 68 | |
| Valerie MD | Elevation Oncology | 46 | |
| Peter Facchini | Enveric Biosciences | 60 | |
| Joseph Tucker | Enveric Biosciences | 55 | |
| Sharen Pyatetskaya | Hepion Pharmaceuticals | ||
| Brian Sullivan | Elevation Oncology | N/A | |
| Todd MD | Hepion Pharmaceuticals | 55 | |
| Joseph Ferra | Elevation Oncology | 49 | |
| Stephen MD | Hepion Pharmaceuticals | N/A | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| Ibrahim MD | Enveric Biosciences | 55 | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| David Dornan | Elevation Oncology | 46 | |
Management Performance
| Return On Equity | -0.97 | |||
| Return On Asset | -0.52 |
Rain Therapeutics Leadership Team
Elected by the shareholders, the Rain Therapeutics' board of directors comprises two types of representatives: Rain Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rain. The board's role is to monitor Rain Therapeutics' management team and ensure that shareholders' interests are well served. Rain Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rain Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Josephine Bruce, Principal officer | ||
| Richard Bryce, Ex Officer | ||
| Vijaya Tirunagaru, Senior Research | ||
| Lucio Tozzi, VP Operations | ||
| Nora MD, MD Development | ||
| Nelson Cabatuan, Sr Admin | ||
| Avanish MBA, CEO CoFounder | ||
| Mehdi Paborji, VP Operations | ||
| Theresa MS, Director Operations | ||
| Buenaflor MPH, Head VP | ||
| Erik Atkisson, General Officer | ||
| Charmi Turner, Vice Culture |
Rain Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rain Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.97 | |||
| Return On Asset | -0.52 | |||
| Current Valuation | (32.85 M) | |||
| Shares Outstanding | 27.58 M | |||
| Shares Owned By Insiders | 16.48 % | |||
| Shares Owned By Institutions | 68.38 % | |||
| Number Of Shares Shorted | 661.11 K | |||
| Price To Book | 0.65 X | |||
| EBITDA | (73.56 M) | |||
| Net Income | (72.26 M) |
Pair Trading with Rain Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rain Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rain Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Rain Stock
Moving against Rain Stock
| 0.84 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.84 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
| 0.8 | HPQ | HP Inc | PairCorr |
| 0.79 | CSCO | Cisco Systems Aggressive Push | PairCorr |
| 0.72 | XOM | Exxon Mobil Corp Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Rain Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rain Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rain Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rain Therapeutics to buy it.
The correlation of Rain Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rain Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rain Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rain Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Rain Stock
If you are still planning to invest in Rain Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rain Therapeutics' history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |